Skip to main content

Living With the Threat of Clostridioides Difficile (C. Difficile) Infection?

Discover A New Path to Wellness Through C. Difficile Infection Clinical Trials

C. difficile is a serious bacterial infection that often develops after antibiotic use, leading to severe diarrhea, abdominal pain, and life-threatening complications. It is one of the most urgent antibiotic-resistant threats, impacting both hospital and community populations.

Revive Research Institute is conducting Clostridium Difficile Clinical Trials to explore investigational vaccine options that may help prevent infection and recurrence. This study is designed to evaluate the safety and effectiveness of a potential vaccine aimed at reducing the burden of C. difficile, which can cause recurrent and severe illness.

Are You Eligible to Participate?

To be eligible for C. diff clinical trials in Michigan, participants must:

  • Be 50 years of age or older
  • Have recent risk factors such as prior hospitalizations, frequent outpatient or emergency visits

*Additional criteria may apply.

Participation in Clostridium Difficile Infection Clinical Trials in Michigan may provide access to expert care, study-related monitoring, and investigational vaccines at no cost. Insurance is not required.

This field is for validation purposes and should be left unchanged.
Who is this information for?*(Required)

Please provide YOUR contact information only.

Name(Required)
Best Time to Call(Required)
User Agreement(Required)
For more info, please visit Privacy Policy.
C. Difficile Infection Clinical Trials Flyer

About the Clinical Trials for C. Difficile Infection

C. difficile infection (CDI) causes symptoms ranging from mild diarrhea to life-threatening conditions such as pseudomembranous colitis, toxic megacolon, and kidney failure. Older adults, with underlying conditions like chronic kidney or heart disease, are at increased risk.

Revive Research Institute is conducting Clostridium Difficile Clinical Trials to study an investigational C. difficile adjuvanted vaccine. To ensure study eligibility, all participants must comply with all study procedures. Participants who meet the eligibility criteria after undergoing the screening phase and are chosen to participate will be given the study treatment.

*All study procedures and study-related treatments, including the investigational drug, are provided at no cost, and no insurance is required to participate, and participants may receive compensation for time and travel.

*To take the next step, submit the form above, and our research staff will contact you to determine if you qualify for the study. A brief discussion about your health and medical history may be required.

Get Started: What to Expect?

If you qualify for a Clostridium Difficile Clinical Trial in Michigan, you may have access to potential vaccine options that target this infection. After completing the interest from above, a research team member will contact you for a brief pre-screening to see if you meet the initial eligibility criteria. If you qualify, you will be asked to review and sign an Informed Consent Form (ICF), which explains all study procedures, potential benefits, and risks.

Following your consent, you will be invited to a screening visit at our clinical research site. During this initial visit, we will ask questions about your medical history, perform physical exams, and run lab tests to further assess your eligibility. If you meet all study requirements, you will be officially enrolled in C. Difficile Infection Clinical Trials.

Our team will ensure you fully understand your role in the study and what to expect throughout the process. You are encouraged to ask any questions before enrolling. Your participation helps advance future treatments for C. difficile infection.

Age:

≥50 Years

Condition:

At Risk for C. Difficile Infection

Location:

Michigan

Understanding C. Difficile Infection

C. Difficile Infection Clinical Trials

Symptoms include:

  • Severe watery diarrhea (up to 15 times/day)
  • Abdominal pain and cramping
  • Fever, nausea, and dehydration
  • Loss of appetite and weight loss
  • Blood or pus in stool
  • Complications such as kidney failure

Risk factors include:

  • Age 50 or older
  • Recent antibiotic use
  • Prolonged hospital stays
  • Chronic health conditions (kidney, liver, cardiac, or lung disease)

Currently, there is no approved vaccine for C. difficile, which makes Clostridium Difficile Infection Clinical Trials in Michigan critical for developing preventive strategies.

Frequently Asked Questions (FAQs)

What is C. difficile infection?

It’s a bacterial infection of the gut that often develops after antibiotic use. It can cause anything from mild diarrhea to severe, life-threatening complications.

Why is it dangerous?

CDI can lead to severe dehydration, intestinal perforation, kidney failure, and even death if untreated.

How is it treated now?

Current treatments include antibiotics such as vancomycin or fidaxomicin. However, recurrence rates remain high, making prevention strategies like vaccination essential.

Why should I participate in a clinical trial?

By joining, you may gain access to a potential vaccine at no cost, receive close medical monitoring, and contribute to research that could protect future generations from this serious infection.

Close Menu

Revive Research Institute, Inc.

28270 Franklin Road
Southfield, MI
48034

T: 248-564-1485
E: info@rev-research.com